Posted by Michael Wonder on 02 Mar 2022
Lenvima (lenvatinib) plus Keytruda (pembrolizumab) approved in Japan for radically unresectable or metastatic renal cell carcinoma
25 February 2022 - Results from CLEAR/KEYNOTE-581 showed Lenvima plus Keytruda significantly reduced the risk of disease progression or death by 61%, with a median progression-free survival of nearly two years versus nine months for sunitinib.
Eisai and Merck today announced that the Japanese Ministry of Health, Labour and Welfare has approved the combination of Lenvima plus Keytruda for radically unresectable or metastatic renal cell carcinoma.
